tetano
Editor, Senior Moderator
Sci Rep
. 2023 Mar 27;13(1):4961.
doi: 10.1038/s41598-023-31114-9.
Performance evaluation of newly developed surrogate virus neutralization tests for detecting neutralizing antibodies against SARS-CoV-2
Oh Joo Kweon[SUP] #[/SUP][SUP] 1 [/SUP], Joon-Yong Bae[SUP] #[/SUP][SUP] 2 [/SUP], Yong Kwan Lim[SUP] 1 [/SUP], Yoojeong Choi[SUP] 1 [/SUP], Sohyun Lee[SUP] 2 [/SUP], Man-Seong Park[SUP] 2 [/SUP], In Bum Suh[SUP] 3 [/SUP], Hana Kim[SUP] 3 [/SUP], Young Sam Jee[SUP] 3 [/SUP], Mi-Kyung Lee[SUP] 4 [/SUP]
Affiliations
Abstract
We evaluated newly developed surrogate virus neutralization tests (sVNT) for detecting neutralizing antibodies (NAbs) against the receptor binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VERI-Q SARS-CoV-2 Neutralizing Antibody Detection ELISA Kit (MiCo BioMed, Gyeonggi-do, Republic of Korea, hereafter, "eCoV-CN") is an enzyme-linked immunosorbent assay-based sVNT, and VERI-Q SARS-CoV-2 Neutralizing Antibody Rapid Test Kit (MiCo BioMed, hereafter, "rCoV-RN") is a point-of-care lateral-flow immunochromatography test with auto-scanner. A total of 411 serum samples were evaluated. Both evaluations used a 50% plaque reduction neutralization test (PRNT[SUB]50[/SUB]) as the gold standard. Compared with PRNT[SUB]50[/SUB], the eCoV-CN showed 98.7% positive percent agreement (PPA), 96.8% negative percent agreement (NPA), 97.4% total percent agreement (TPA), with kappa values of 0.942. The rCoV-RN showed 98.7% PPA, 97.4% NPA, 97.8% TPA, and kappa values of 0.951, comparing to PRNT[SUB]50[/SUB]. Neither assay indicated cross-reactivity for other pathogens, and the signal indexes were statistically significantly correlated to the PRNT[SUB]50[/SUB] titer. The two evaluated sVNTs show comparable performances to the PRNT[SUB]50[/SUB] with the advantages of technical simplicity, speed, and do not require cell culture facilities.
. 2023 Mar 27;13(1):4961.
doi: 10.1038/s41598-023-31114-9.
Performance evaluation of newly developed surrogate virus neutralization tests for detecting neutralizing antibodies against SARS-CoV-2
Oh Joo Kweon[SUP] #[/SUP][SUP] 1 [/SUP], Joon-Yong Bae[SUP] #[/SUP][SUP] 2 [/SUP], Yong Kwan Lim[SUP] 1 [/SUP], Yoojeong Choi[SUP] 1 [/SUP], Sohyun Lee[SUP] 2 [/SUP], Man-Seong Park[SUP] 2 [/SUP], In Bum Suh[SUP] 3 [/SUP], Hana Kim[SUP] 3 [/SUP], Young Sam Jee[SUP] 3 [/SUP], Mi-Kyung Lee[SUP] 4 [/SUP]
Affiliations
- PMID: 36973368
- DOI: 10.1038/s41598-023-31114-9
Abstract
We evaluated newly developed surrogate virus neutralization tests (sVNT) for detecting neutralizing antibodies (NAbs) against the receptor binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VERI-Q SARS-CoV-2 Neutralizing Antibody Detection ELISA Kit (MiCo BioMed, Gyeonggi-do, Republic of Korea, hereafter, "eCoV-CN") is an enzyme-linked immunosorbent assay-based sVNT, and VERI-Q SARS-CoV-2 Neutralizing Antibody Rapid Test Kit (MiCo BioMed, hereafter, "rCoV-RN") is a point-of-care lateral-flow immunochromatography test with auto-scanner. A total of 411 serum samples were evaluated. Both evaluations used a 50% plaque reduction neutralization test (PRNT[SUB]50[/SUB]) as the gold standard. Compared with PRNT[SUB]50[/SUB], the eCoV-CN showed 98.7% positive percent agreement (PPA), 96.8% negative percent agreement (NPA), 97.4% total percent agreement (TPA), with kappa values of 0.942. The rCoV-RN showed 98.7% PPA, 97.4% NPA, 97.8% TPA, and kappa values of 0.951, comparing to PRNT[SUB]50[/SUB]. Neither assay indicated cross-reactivity for other pathogens, and the signal indexes were statistically significantly correlated to the PRNT[SUB]50[/SUB] titer. The two evaluated sVNTs show comparable performances to the PRNT[SUB]50[/SUB] with the advantages of technical simplicity, speed, and do not require cell culture facilities.